SavedAdd your journal

Journals / Çocuk Dergisi / 2026 / Cilt: 23 Sayı: 4

30 Years of Wilms Tumor Experience at One Center in Türkiye’s Central Anatolia Region

Şefika Akyol(Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Oncology & HSCT Center)0000-0003-0051-4274
Gül Pelin Odabaş(Erciyes University, Faculty of Medicine, Department of Pediatrics)0000-0003-4242-1789
Alper Özcan(Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Oncology & HSCT Center)0000-0002-6100-1205
Ebru Yılmaz(Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Oncology & HSCT Center)0000-0003-4802-0986
Zehra Filiz Karaman(Erciyes University, Faculty of Medicine Division of Pediatric Radiology, Department of Radiology)0000-0003-4552-8098
Figen Öztürk(ERCIYES UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF SURGICAL MEDICAL SCIENCES, DEPARTMENT OF PATHOLOGY)0000-0001-6180-5716
Hülya Akgün(ERCIYES UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF SURGICAL MEDICAL SCIENCES, DEPARTMENT OF PATHOLOGY)0000-0002-0513-0045
Ahmet Burak Doğan(ERCIYES UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF SURGICAL MEDICAL SCIENCES, DEPARTMENT OF PEDIATRIC SURGERY)0000-0003-1544-4598
Celalettin Eroğlu(ERCIYES UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF RADIATION ONCOLOGY)0000-0002-5743-2440
Ekrem Ünal(HASAN KALYONCU UNIVERSITY, FACULTY OF HEALTH SCIENCES, DEPARTMENT OF NURSING)0000-0002-2691-4826
Musa Karakükçü(Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Oncology & HSCT Center)0000-0003-2015-3541
Pages
344–348
Publication Date
2024-02-20
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with an unfavorable histology had a 66.7% chance of both event-free survival (EFS) and overall survival (OS), which is lower than the respective 85.2% and 92.1% odds of EFS and OS for the favorable histology group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The current study aims to evaluate the clinical presentation, treatment, and follow-up of children with Wilms Tumor (WT) who had been admitted to Erciyes University, Faculty of Medicine Department of Pediatric Hematology and Oncology hospital, a tertiary center in the central Anatolia region of Türkiye.
📊
Key Findings & Data:Materials and Methods: The current study has been planned as a retrospective observational evaluation of patients admitted to the Pediatric Hematology and Oncology Center between 1991-2021.
💡
Conclusion & Impact:Patients with an unfavorable histology had a 66.7% chance of both event-free survival (EFS) and overall survival (OS), which is lower than the respective 85.2% and 92.1% odds of EFS and OS for the favorable histology group.
🔬Design:Araştırma Makalesi
📍Scope:2021 Verileri
⚙️Variables:Wilms Tumor · Event-Free Survival · Overall Survival

Abstract

Objective: The current study aims to evaluate the clinical presentation, treatment, and follow-up of children with Wilms Tumor (WT) who had been admitted to Erciyes University, Faculty of Medicine Department of Pediatric Hematology and Oncology hospital, a tertiary center in the central Anatolia region of Türkiye. The study assesses the survival data and features that have had an impact on survival. Materials and Methods: The current study has been planned as a retrospective observational evaluation of patients admitted to the Pediatric Hematology and Oncology Center between 1991-2021. Results: The study retrospectively evaluated a total of 48 patients in terms of demographic characteristics, presentation findings, tumor stages, histopathologies, and survival rates. Patients with an unfavorable histology had a 66.7% chance of both event-free survival (EFS) and overall survival (OS), which is lower than the respective 85.2% and 92.1% odds of EFS and OS for the favorable histology group. However, this is not statistically significant (p = 0.20 for EFS and p = 0.05 for OS). Regarding the impact of stage on survival rates, the EFS and OS for patients with the low-stage disease were 88% and 95.7%, respectively. These rates were significantly superior to those at an advanced stage of the disease, whose EFS and OS were 63.1% and 60.9%, respectively (p = 0.042 for EFS, p = 0.005 for OS). Conclusion: Wilms tumor at an advanced stage and with an unfavorable histology are the major factors resulting in poor survival rates.

🔖

Cite This Article

Akyol, Ş., Odabaş, G. P., Özcan, A., Yılmaz, E., Karaman, Z. F., Öztürk, F., Akgün, H., Doğan, A. B., Eroğlu, C., Ünal, E., Karakükçü, M. (2024). 30 Years of Wilms Tumor Experience at One Center in Türkiye’s Central Anatolia Region. Çocuk Dergisi, Cilt: 23 Sayı: 4, 344–348. https://doi.org/10.26650/jchild.2023.1308863

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Fernandez CV, Geller JI, Ehrlich PF, et al. Renal Tumors, in Pizzo&Poplack’s Pediatric Oncology.2021, Philadelphia.pp 525-540. google scholar
  2. Özyörük D, Emir S. The management of bilateral Wilms tumor. Transl Pediatr. 2014;3(1):34-38. google scholar
  3. Akyuz C, Yalcin B, Yildiz I, et al. Treatment of Wilms tumor: a report from the Turkish Pediatric Oncology Group (TPOG). Pediatr Hematol Oncol, 27(3): p. 161-178, 2010. google scholar
  4. Aydın B, Akyüz C, Yalçın B, Ekinci S, Oğuz B, Akçören Z, Yıldız F, Varan A, Kurucu N, Büyükpamukçu M, Kutluk T. Bilateral Wilms tumors: Treatment results from a single center. Turk J Pediatr. 2019;61(1):44-51. google scholar
  5. Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol. 2015 Sep 20;33(27):2999-3007. google scholar
  6. Kara B, Sarıkaya M, Ertan K, Uğraş NS, Çiftçi İ, Yavaş G, et al. Çocuklarda primer böbrek tümörlerinin klinik özellikleri, tedavi yaklaşımları ve tedavi sonuçları. Genel Tıp Dergisi. 2021; 31(4): 375-379. google scholar
  7. Libes J, Hol J, Neto JCA, et al. Pediatric renal tumor epidemiology: Global perspectives, progress, and challenges. Pediatr Blood Cancer. 2023;70(1):e30006. google scholar
  8. Ünal E, Yilmaz E, Özcan A, Işik B, Karakükcü M, Turan C, et al. Twenty children with non-Wilms renal tumors from a reference center in Central Anatolia, Turkey. Turk J Med Sci. 2020 Feb 13;50(1):18-24. google scholar
  9. Brok J, Treger TD, Gooskens SL, et al. Biology and treatment of renal tumours in childhood. Eur J Cancer 2016;68:179-195. google scholar
  10. Jeffrey S. Dome EAM, Pedram Argani, Pediatric Renal Tumors, in Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. 2015, Saunders: Philadelphia. p. 1714-1746. google scholar
  11. Vujanic GM, Gessler M, Ooms AHAG, et al; International Society of Paediatric Oncology-Renal Tumour Study Group (SIOP-RTSG). The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2018 Nov;15(11):693-701. google scholar
  12. Turner JT, Brzezinski J, Dome JS. Wilms Tumor Predisposition. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; December 19, 2003. google scholar
  13. Richard H. Scott NR, Genetic Predisposition to Wilms Tumor, in Renal Tumors of Childhood, J.S.D. Kathy Pritchard-Jones, Editor. 2014, Springer: Berlin. p. 19-38. google scholar
  14. Pater L, Melchior P, Rübe C, et al. Wilms tumor. Pediatr Blood Cancer. 2021;68 Suppl 2:e28257. google scholar
  15. Perlman EJ, Grundy PE, Anderson JR, et al.WT1 mutation and 11p15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a Children’s Oncology Group study. J Clin Oncol. 2011;29:698-703. google scholar
  16. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23:7312-7321. google scholar
  17. Vujanic GM, Sandstedt B, Harms D, et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol. 2002; 38(2):79-82. google scholar
  18. D’Angio GJ. The National Wilms Tumor Study: a 40 year perspective. Lifetime Data Anal. 2007;13(4):463-470. google scholar
  19. Kieran K, Anderson JR, DomeJS, et al. Is adrenalectomy necessary during unilateral nephrectomy for Wilms tumor? A report from the Children’s Oncology Group. J Pediatr Surg. 2013;48:1598-1603. google scholar
  20. Fernandez CV, Perlman EJ, Mullen EA, et al. Clinical outcome and biologic predictors of relapse after nephrectomy only for very low risk Wilms tumor: a report from the Children’s Oncology Group AREN0532. Ann Surg. 2017;265:835-840. google scholar
  21. Kalapurakal JA, Li SM, Breslow NE, et al. Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms’ tumor treated on NWTS-3 and NWTS-4: a report from the National Wilms Tumor Study group. Int J Radiat Oncol Biol Phys. 2003;57:495-499. google scholar
  22. Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms’ tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015;386:1156-1164. google scholar
  23. SIOP Renal Tumour Study Group. Paediatric renal tumours: perspectives from the SIOP-RTSG. Nat Rev Urol. 2017;14:3-4. google scholar
  24. Elmalı A, Sarı SY, Akyüz C, Gültekin M, Yalçın B, Ayrın B, et al. De-escalated Radiotherapy for Advanced Stage Wilms’ Tumor. Turk J Oncol 2023;38(1):66—74 google scholar
  25. Stokes CL, StokesWA, Kalapurakal JA, et al. Timing of radiation therapy in pediatric Wilms tumor: a report from the National Cancer Database. Int J Radiat Oncol Biol Phys. 2018;101:453-461. google scholar